Brokerages Expect Juno Therapeutics, Inc. (JUNO) to Post -$1.15 Earnings Per Share

Wall Street analysts forecast that Juno Therapeutics, Inc. (NASDAQ:JUNO) will post earnings of ($1.15) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Juno Therapeutics’ earnings. Juno Therapeutics reported earnings per share of ($0.65) during the same quarter last year, which would indicate a negative year-over-year growth rate of 76.9%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 7th.

On average, analysts expect that Juno Therapeutics will report full-year earnings of ($3.34) per share for the current financial year. For the next financial year, analysts expect that the firm will report earnings of ($4.26) per share, with EPS estimates ranging from ($4.35) to ($4.17). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Juno Therapeutics.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.57) earnings per share.

JUNO has been the topic of a number of research analyst reports. BTIG Research raised Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, August 28th. Zacks Investment Research lowered Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Wedbush raised Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price target on the stock in a research note on Tuesday, August 29th. Raymond James Financial raised Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target on the stock in a research note on Tuesday, August 29th. Finally, ValuEngine raised Juno Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. Juno Therapeutics has a consensus rating of “Hold” and a consensus target price of $45.48.

In related news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert Azelby sold 6,666 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares in the company, valued at approximately $4,395,890.10. The disclosure for this sale can be found here. Company insiders own 15.08% of the company’s stock.

Large investors have recently bought and sold shares of the business. Advisor Group Inc. raised its position in Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,439 shares during the period. The Manufacturers Life Insurance Company raised its position in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics in the second quarter valued at $105,000. Bronfman E.L. Rothschild L.P. raised its position in Juno Therapeutics by 27,376.9% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 3,559 shares during the period. Finally, QS Investors LLC purchased a new stake in Juno Therapeutics in the second quarter valued at $135,000. Institutional investors own 70.37% of the company’s stock.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down $3.24 during trading hours on Friday, hitting $44.17. The stock had a trading volume of 4,361,000 shares, compared to its average volume of 2,092,505. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $63.45.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Juno Therapeutics, Inc. (JUNO) to Post -$1.15 Earnings Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/15/brokerages-expect-juno-therapeutics-inc-juno-to-post-1-15-earnings-per-share.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply